Integrated genomic and epigenomic analysis of circulating tumor DNA from patients with malignant melanoma

Not Applicable

• Conditions: malignant melanoma

• Registration Number: JPRN-UMIN000042040
• Lead Sponsor: ational Cancer Center Hospital East

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-07
• Last Update Posted: 17 October 2023
• Study Completion: 2028-03-31

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1.A history of active malignancy within 5 years of disease-free status. However, patients with basal cell carcinoma or spinous cell carcinoma of the skin, superficial bladder cancer, cervical cancer, endoscopically curable carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma equivalent lesions, or non-metastatic prostate cancer that does not require systemic treatment, who are judged to be cured by local treatment, will be enrolled in the registry if they are disease-free for 5 years or less It shall be possible. 2.Duplicate cancers are suspected on head, neck, thorax and abdomen and pelvic contrast CT scan within 60 days prior to enrollment. 3.Women who are pregnant. 4.Your physician determines that you are unsuitable for enrollment in this study.

Study & Design

• Study Type: Observational
• Study Design: Not specified